Loading…
Provider of virtual health care services, including telehealth visits, chronic condition management and mental health care.
Provider of virtual health care services, including telehealth visits, chronic condition management and mental health care.
Integrated Care is sold to employers and health plans for a fixed monthly fee per enrolled member, with extra charges per visit, while BetterHelp sells therapy subscriptions straight to consumers who pay out of pocket and are won through heavy online advertising.
Moat: narrow (scale, brand, data). Large telehealth user base and employer/health-plan contracts, though facing intensifying low-cost competition.
Headquarters: Purchase, New York · Founded: 2002 · Employees: 5,600
Size Teladoc Health (TDOC) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.60B, the 1947th largest of 3,117 United States companies the cockpit tracks. Shares closed at $8.77 on 6 Nov 2026.
Performance Over six months the shares gained 21.0%, against +18.2% for the median peer and -1.1% for the United States market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue fell 2.4% over the last twelve months (peer median +7.9%); the operating margin is -5.4% (peer median 4.7%).
Valuation It trades at 0.7× enterprise value to sales against a peer median of 2.2× (2nd cheapest of 21).
Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -23 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 18.2 points below its cost of capital (11.2% WACC).
Credit Teladoc Health has 1 bond outstanding ($1.00B).
Short interest Short interest is 17.6% of the free float (15 Oct 2026).
Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $2.47B | $2.53B | $2.57B | $2.60B | $2.41B |
| Revenue growth | — | -2% | -1% | +8% | — |
| Gross profit | $1.32B | $1.39B | $1.44B | $1.51B | $1.41B |
| EBITDA | $246M | $213M | $174M | $141M | $43.3M |
| Net income | -$155M | -$200M | -$1.00B | -$220M | -$13.7B |
| Free cash flow | $262M | $281M | $283M | $339M | $173M |
| Capital expenditure | $142M | $157M | $124M | $156M | $173M |
| Total debt | $1.04B | $1.04B | $1.58B | $1.59B | $1.59B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Teladoc Health TDOC | $1.60B | +21% | -2% | -5% | 0.7× | -5.2% |
| Hims & Hers Health HIMS | $6.07B | -8% | +28% | 0% | 2.6× | 54.9% |
| CVS Health CVS | $107B | -7% | +7% | 4% | 0.4× | -3.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TDOC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +58.3% | +7.3% | highest of 21 |
| 6-month return | +21.0% | +18.2% | 11th highest of 21 |
| Distance from 52-week high | -11.3% | -17.1% | 8th highest of 21 |
| Revenue growth (TTM) | -2.4% | +7.9% | 5th lowest of 21 |
| Operating margin | -5.4% | 4.7% | 5th lowest of 21 |
| EV / Sales | 0.7× | 2.2× | 2nd cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | -5.2% | 17.4% | least demanding of 15 |
| Growth delivered (Del g) | +18.3% | +8.7% | 4th highest of 15 |
| Hurdle (Req g minus delivered) | -23.4 pp | +10.4 pp | least demanding of 15 |
| ROIC minus cost of capital | -18.2 pp | -3.7 pp | 4th lowest of 20 |
| EV / EBITDA | 7.3× | 22.6× | cheapest of 14 |
| Net debt / EBITDA | 0.8× | 2.8× | 6th least indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Teladoc Health TDOC | United States | $1.60B | +21% | -2% | -5% | 0.7× | -5.2% | +18.3% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.60B | +22% | +24% | 32% | 16.8× | 39.3% | +16.7% |
| Sonida Senior Living SNDA | United States | $1.58B | -14% | +49% | -11% | 5.9× | n/a | n/a |
| Ambea AMBEA.ST | Sweden | $1.63B | +30% | +13% | 8% | 1.7× | 1.7% | +7.7% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.63B | -47% | +8% | 3% | 0.7× | 15.0% | -5.1% |
| Personalis PSNL | United States | $1.71B | +164% | -13% | -164% | 22.1× | n/a | n/a |
| Azenta AZTA | United States | $1.72B | +104% | +1% | -3% | 2.4× | 56.0% | +8.9% |
| U.S. Physical Therapy USPH | United States | $1.48B | +68% | +11% | 10% | 2.7× | 19.9% | +13.0% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.74B | +15% | +22% | 15% | 7.4× | 41.9% | +26.9% |
| Clariane CLARI.PA | France | $1.40B | -20% | +1% | 6% | 1.6× | 6.7% | +6.5% |
| GeneDx WGS | United States | $1.86B | +53% | +25% | -12% | 4.2× | n/a | n/a |
| H.U.Group 4544.T | Japan | $1.35B | +24% | +1% | 2% | 0.9× | 10.1% | +2.1% |
| agilon health AGL | United States | $1.90B | +109% | 0% | -4% | 0.3× | n/a | n/a |
| Emeis EMEIS.PA | France | $1.94B | -30% | +4% | 3% | 1.6× | 21.3% | +8.5% |
| Dian Diagnostics 300244.SZ | China | $1.97B | +11% | -5% | 9% | 1.5× | 2.4% | -1.1% |
| Diagnostyka DIA.WA | Poland | $1.29B | -5% | +19% | 15% | 2.4× | 6.9% | +18.9% |
| OPKO Health OPK | United States | $1.29B | +52% | -11% | -29% | 2.4× | n/a | n/a |
| Lumexa Imaging LMRI | United States | $1.29B | +29% | +8% | 3% | 2.1× | n/a | n/a |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.99B | +5% | -3% | 7% | 2.0× | 6.7% | -6.1% |
| Pennant PNTG | United States | $1.27B | +1% | +38% | 6% | 1.6× | 21.1% | +19.4% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +12% | +20% | 18% | 6.6× | 32.4% | +10.5% |
Teladoc Health has 1 bond outstanding with $1.00B face value.